281 related articles for article (PubMed ID: 26523170)
1. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
2. Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine.
Ljubojevic Hadzavdic S; Stulhofer Buzina D; Murtezani I; Skerlev M
J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e304-e306. PubMed ID: 27987319
[No Abstract] [Full Text] [Related]
3. Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer.
Sánchez-Gundín J; Torres-Suárez AI; Fernández-Carballido AM; Barreda-Hernández D
Farm Hosp; 2019 Sep; 43(5):158-162. PubMed ID: 31469628
[TBL] [Abstract][Full Text] [Related]
4. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
[TBL] [Abstract][Full Text] [Related]
5. Unilateral Capecitabine-related Hand-foot Syndrome.
Matsuda S; Koketsu H; Hayakawa M; Nagata N
Intern Med; 2015; 54(21):2779. PubMed ID: 26521911
[No Abstract] [Full Text] [Related]
6. A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Charalambous A; Tsitsi T; Astras G; Paikousis L; Filippou E
Eur J Oncol Nurs; 2021 Feb; 50():101866. PubMed ID: 33227569
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Hand-foot Syndrome: A Case Report.
Uppala PK; Varghese AM; Yella SST; Velmurugan H; Thangaraju P; Krishna Sasanka KSBS
Infect Disord Drug Targets; 2023; 23(1):e140622205973. PubMed ID: 35708076
[TBL] [Abstract][Full Text] [Related]
8. "Hand-foot" syndrome-an unusual case of plantar pathology presenting to a burns unit.
Goutos I; Kaniorou-Larai M; Dziewulski P
J Burn Care Res; 2009; 30(3):529-32. PubMed ID: 19349881
[TBL] [Abstract][Full Text] [Related]
9. A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
Gratiaux J; Gossery C; Rezzag-Mahcene C; Botsen D; Visseaux L; Slimano F; Bouche O
J Oncol Pharm Pract; 2022 Jan; 28(1):247-249. PubMed ID: 34233543
[TBL] [Abstract][Full Text] [Related]
10. The concurrence of subacute cutaneous lupus erythematosus and hand-foot syndrome in a patient undergoing capecitabine chemotherapy.
Li Z; Jiang N; Xu Y
Australas J Dermatol; 2016 Feb; 57(1):e14-6. PubMed ID: 25495707
[TBL] [Abstract][Full Text] [Related]
11. An exploratory study to identify risk factors for the development of capecitabine-induced Palmar Plantar Erythrodysesthesia (PPE).
Law A; Dyson S; Anthony D
J Adv Nurs; 2015 Aug; 71(8):1825-32. PubMed ID: 25702709
[TBL] [Abstract][Full Text] [Related]
12. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia.
King TL; Voon PJ; Yuen KH; Mohamed Noor DA
Support Care Cancer; 2024 May; 32(6):345. PubMed ID: 38743316
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature.
Harris CS; Wang D; Carulli A
J Oncol Pharm Pract; 2014 Feb; 20(1):73-80. PubMed ID: 23478198
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine Toxicity and Dihydropyrimidine Dehydrogenase Deficiency.
Tariq Z; Mudge R; Phillips S
Am J Ther; 2018; 25(6):e742-e743. PubMed ID: 29889674
[No Abstract] [Full Text] [Related]
15. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine-induced lichenoid drug eruption: a case report.
Gehlhausen JR; Strausburg MB; Aouthmany M; Katona TM; Turner MJ
Dermatol Online J; 2017 Feb; 23(2):. PubMed ID: 28329488
[TBL] [Abstract][Full Text] [Related]
19. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
Law CC; Fu YT; Chau KK; Choy TS; So PF; Wong KH
Dis Colon Rectum; 2007 Dec; 50(12):2180-7. PubMed ID: 17963003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
